학술논문
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron—results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)
Document Type
Original Paper
Author
Hopff, Sina M.; Appel, Katharina S.; Miljukov, Olga; Schneider, Johannes; Addo, Marylyn M.; Bals, Robert; Bercker, Sven; Blaschke, Sabine; Bröhl, Isabel; Büchner, Nikolaus; Dashti, Hiwa; Erber, Johanna; Friedrichs, Anette; Geisler, Ramsia; Göpel, Siri; Hagen, Marina; Hanses, Frank; Jensen, Björn-Erik Ole; Keul, Maria; Krawczyk, Adalbert; Lorenz-Depiereux, Bettina; Meybohm, Patrick; Milovanovic, Milena; Mitrov, Lazar; Nürnberger, Carolin; Obst, Wilfried; Römmele, Christoph; Schäfer, Christian; Scheer, Christian; Scherer, Margarete; Schmidt, Julia; Seibel, Kristina; Sikdar, Shimita; Tebbe, Johannes Josef; Tepasse, Phil-Robin; Thelen, Philipp; Vehreschild, Maria J. G. T.; Weismantel, Christina; Vehreschild, J. Janne
Source
Infection: A Journal of Infectious Diseases. :1-15
Subject
Language
English
ISSN
0300-8126
1439-0973
1439-0973
Abstract
Purpose: The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron.Methods: We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points.Results: We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73–0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron.Conclusion: With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU.Clinical Trail registration: The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).